Filters
Multiparametric magnetic resonance imaging and magnetic resonance elastography to evaluate the early effects of bariatric surgery on non-alcoholic liver disease
Tan, H. C., et al. (2023)
International Journal of Biomedical Imaging
Read Summary ▾
This first-of-its-kind study used LiverMultiScan and MRE to assess NAFLD in patients with morbid obesity over a six-month period following bariatric surgery. Liver disease activity (cT1) and liver fat (PDFF) significantly improved, but there was no change in liver stiffness (MRE). These results highlight LiverMultiScan’s utility for detecting early, clinically meaningful change during postoperative monitoring.
A composite score using quantitative magnetic resonance cholangiopancreatography predicts clinical outcomes in primary sclerosing cholangitis
Vuppalanchi, R., et al. (2023)
JHEP Reports
Read Summary ▾
First validated prognostic model of clinical outcomes in PSC using a novel composite marker derived from quantitative MRCP metrics, bilirubin, and AST. It outperformed the traditional Mayo risk score in predicting transplant-free survival in patients with PSC, suggesting improved risk stratification and potential to improve clinical management.
Growth hormone administration improves nonalcoholic fatty liver disease in overweight/obesity: a randomized trial
Dichtel, L. E., et al. (2023)
The Journal of Clinical Endocrinology and Metabolism
Read Summary ▾
Growth hormone (GH) administration for six months showed promising results in ameliorating NAFLD in overweight and obese individuals. Specifically, cT1 measurements revealed significant improvements in liver disease activity, suggesting the potential of GH therapy as a novel approach for managing NAFLD in this population.
A low-energy total diet replacement program demonstrates a favorable safety profile and improves liver disease severity in nonalcoholic steatohepatitis
Koutoukidis, D. A., et al. (2023)
Obesity
Read Summary ▾
In NASH patients with obesity and fibrosis on a low-energy total diet replacement, LiverMultiScan cT1 detected significant reductions in liver disease activity. Compared to other NITs (CAP, MRE, VCTE), cT1 was the only consistent and reliable biomarker that captured change in liver disease severity, highlighting its utility for monitoring response to diet and lifestyle interventions.
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Loomba, R., et al. (2023)
The New England Journal of Medicine
Read Summary ▾
In this phase 2b randomized controlled trial, treatment with FGF21 analogue pegozafermin, a novel therapy for treating NASH, led to improvements in liver fat and fibro-inflammation (liver disease activity) quantified by cT1 from baseline up to 24 weeks. These results support the advancement of pegozafermin into phase 3 development.
To pay or not to pay for artificial intelligence applications in radiology
Lobig, F., et al. (2023)
NPJ Digital Medicine
Read Summary ▾
This review on the value of AI-supported digital applications in radiology describes LiverMultiScan as a tool detecting liver diseases with a high degree of accuracy compared to gold-standard liver biopsies, delivering comparable diagnostic information without the risks associated with an invasive procedure. It also reports that LiverMultiScan-derived parameters strongly predict clinical outcomes.
Liver disease is a significant risk factor for cardiovascular outcomes
Roca-Fernandez, A., et al. (2023)
JHEP Reports
Read Summary ▾
Patients with increased liver disease activity (cT1) were more likely to develop cardiac conditions. Specifically, individuals with increased cT1 were ~30% more likely to be hospitalized due to a major adverse cardiovascular event. Findings suggest liver disease activity is a meaningful risk factor for heart disease and support cT1 for cardiovascular risk stratification.
Bayesian-networks and imaging derived phenotypes highlight the role of fat deposition on risk of hospitalisation risk with COVID-19
Waddell, T., et al. (2023)
Frontiers in Bioinformatics
Read Summary ▾
Using Bayesian-network modeling, this study links body-fat distribution to COVID-19 hospitalization risk. Obesity increased risk versus normal weight; across all BMI groups, higher visceral fat and liver fat were associated with markedly greater hospitalization probability. Findings underscore multi-organ imaging and Bayesian models for understanding and stratifying COVID-19 risk.
AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Rinella, M. E., et al. (2023)
Hepatology
Read Summary ▾
AASLD’s new practice guidance on the clinical management of NAFLD recommends sequentially integrating cT1 with other noninvasive tests for the identification and risk-stratification of patients with “at-risk” NASH in secondary/speciality care to facilitate better clinical management of these patients.
Right and left liver lobe biopsies by minilaparoscopy reveal clinically significant sampling error in staging and grading of autoimmune hepatitis
Johannes, H., et al. (2023)
Liver International
Read Summary ▾
An invasive minilaparoscopic biopsy of both liver lobes in AIH (AIH, AIH-PBC, and AIH-PSC) was more accurate for grading/staging disease activity than percutaneous biopsy, reflecting intrahepatic heterogeneity. Noninvasive LiverMultiScan cT1 demonstrated this heterogeneity, and its extent independently predicted disease flares, supporting multi-lobe sampling and cT1 for comprehensive assessment.
Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Tincopa, M. A., & Loomba, R. (2023)
Lancet Gastroenterology & Hepatology
Read Summary ▾
An expert review on advances in noninvasive tests for NAFLD recognizes cT1 as a validated tool for detecting NASH and at-risk NASH, correlating with NAS features and fibrosis. cT1 showed the highest rule-in specificity (90%) among the reviewed noninvasive tests for at-risk NASH at a cut-off of ≥ 875 ms.
Clonal haematopoiesis and risk of chronic liver disease.
Wong, W. J., et al. (2023)
Nature
Read Summary ▾
Across large population cohorts, clonal haematopoiesis of indeterminate potential was linked to higher risk of chronic liver disease, including NASH. Specifically, LiverMultiScan findings in UK Biobank participants revealed a higher prevalence of liver disease activity and liver fat in individuals with CHIP. LiverMultiScan may represent a modifiable risk factor for e.g. blood cancers and cardiovascular disease.
The use of current knowledge and non-invasive testing modalities for predicting at-risk nonalcoholic steatohepatitis and assessing fibrosis
Kugelmas, M., et al. (2023)
Liver International
Read Summary ▾
This expert review proposes a clinical care pathway for suspected NAFLD, positioning cT1 as the key individual biomarker to risk-stratify patients and flag high-risk NASH to facilitate timely management. It further suggests that cT1 could replace or precede liver biopsy in all patients at intermediate/high risk of fibrosis, subject to hepatologist judgment.
Poor glycaemic control and ectopic fat deposition mediates the increased risk of non-alcoholic steatohepatitis in high-risk populations with type-2 diabetes: Insights from Bayesian-network modelling
Waddell, T., et al. (2023)
Frontiers in Endocrinology
Read Summary ▾
Using a Bayesian-network model, this study shows that in high-risk adults with type 2 diabetes, excess liver fat, poor glycaemic control, and excess visceral fat raise NASH risk by 31%, 22%, and 20%, respectively, with important implications for the development of targeted interventions to prevent NASH in high-risk populations.